• leader board size
Consumer Research2020-11-05T23:41:25-08:00

Consumer Research

Tilray Medical Expands to Panama Market

NEW YORK – Tilray Medical, the pharmaceutical arm of Tilray Brands Inc., has secured a medical Cannabis license in Panama, marking its latest step into Central America. The company formed a joint venture with local ...

Cronos Group Reports Q3 2025 Financial Results

TORONTO – Cronos Group Inc., a Canadian Cannabis producer with a growing international footprint, reported third-quarter results that marked new highs for revenue, profitability, and cash reserves, even as domestic challenges in Canada tempered some ...

Cresco Labs Reports Q3 2025 Financial Results

CHICAGO – Cresco Labs, a major player in branded Cannabis products and the Sunnyside retail chain, announced third-quarter results showing revenue of $165 million for the period ended September 30. The figure marked a modest ...

Medical Cannabis: Growth and Investment in 2024

LOS ANGELES- The medical cannabis industry is navigating 2024 with key players like Grow Group and Somai Pharmaceuticals leveraging new regulations and market dynamics to achieve ambitious growth targets. This article examines the recent developments ...

Constellation Brands: Analysts Maintain Ratings

LOS ANGELES- On Monday, Argus reaffirmed its Buy rating on shares of Constellation Brands (NYSE: STZ), maintaining a price target of $306.00. Argus notes the stock's value, currently trading at 18 times the firm's fiscal ...

Critics Slam Thai Government’s Approach to Cannabis

LOS ANGELES- Critics have strongly opposed the Thai government's plan to reclassify cannabis as a narcotic, arguing that it will harm businesses involved in cannabis-based products and undermine investor confidence in the country. On July ...

Constellation Brands: Analysts Maintain Ratings

LOS ANGELES- On Monday, Argus reaffirmed its Buy rating on shares of Constellation Brands,  maintaining a price target of $306.00. Argus notes the stock's value, currently trading at 18 times the firm's fiscal year 2025 ...

Subscribe To Our Newsletter

Go to Top